RT Journal Article
SR Electronic
T1 Systematic Review and Meta-analysis on COVID-19 Vaccine Hesitancy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.15.21257261
DO 10.1101/2021.05.15.21257261
A1 Fathalla Aboelsaad, Iman Ahmed
A1 Hafez, Dina Mohamed
A1 Almaghraby, Abdallah
A1 Abdulmoneim, Shaimaa Abdulaziz
A1 El-ganainy, Samar Ossama
A1 Hamdy, Noha Alaa
A1 Deghidy, Ehsan Akram
A1 El-Deen, Ahmed El-Sayed Nour
A1 Adel Elrewany, Ehab Mohamed
A1 Taha Khalil, Alaa Hamdy
A1 Salem, Karem Mohamed
A1 kabeel, Samar Galal
A1 Mohammed Elhadi, Yasir Ahmed
A1 Shaaban, Ramy
A1 Alnagar, Amr
A1 Fadel Elsherbeny, Eman Ahmad
A1 Elfeshawy, Nagwa Ibrahim
A1 Tahoun, Mohamed Moustafa
A1 Ghazy, Ramy Mohamed
YR 2021
UL http://medrxiv.org/content/early/2021/05/18/2021.05.15.21257261.abstract
AB Background: The presented meta-analysis was developed in response to the publication of several studies addressing COVID-19 vaccines hesitancy. We aimed to identify the proportion of vaccine acceptance and rejection, and factors affecting vaccine hesitancy worldwide especially with the fast emergency approval of vaccines.Methods: Online database search was performed, and relevant studies were included with no language restriction. A meta-analysis was conducted using R software to obtain the random effect model of the pooled prevalence of vaccine acceptance and rejection. Egger’s regression test was performed to assess publication bias. Quality assessment was assessed using Newcastle-Ottawa Scale quality assessment tool.Results: Thirty-nine out of 12246 articles met the predefined inclusion criteria. All studies were cross-sectional designs. The pooled proportion of COVID-19 vaccine hesitancy was 17% (95% CI: 14-20) while the pooled proportion of COVID-19 vaccine acceptance was 75% (95% CI: 71-79). The vaccine hesitancy and the vaccine acceptance showed high heterogeneity (I2=100%). Case fatality ratio and the number of reported cases had significant effect on the vaccine acceptance as the pooled proportion of vaccine acceptance increased by 39.95% (95% CI: 20.1-59.8) for each 1% increase in case fatality (P<0.0001) and decreased by 0.1% (95% CI: -0.2-0.01) for each 1000 reported case of COVID-19, P= 0.0183).Conclusion: Transparency in reporting the number of newly diagnosed COVID-19 cases and deaths is mandatory as these factors are the main determinants of COVID-19 vaccine acceptance.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:secondary data analysis, meta-analysisAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yessystematic review and meta-analysisAESIAdverse Events of Special InterestCAWIComputer Assisted Web InterviewsCIConfidence IntervalCOVID-19Coronavirus DiseaseFFemaleFDAFood and Drug AdministrationHCWsHealth Care WorkersMMalemRNAMessenger Ribonucleic AcidnNumberNANot AvailablePRISMAPreferred Reporting Items of Systematic Review and Meta-analysisQAQuality AssessmentRRRRelative Risk RatioSARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2SDStandard DeviationSMSShort Message ServiceUKUnited KingdomUSUnited StatesVAERSVaccine Adverse Event Reporting SystemVPDVaccine Preventable DiseasesWHOWorld Health Organization